Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|March 4, 2014
The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of NutlinsSwethajit Biswas, Emma Killick, Aart G Jochemsen, et al.
Oncotarget|October 21, 2017
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancerMaryam Zanjirband, Nicola Curtin, Richard J Edmondson, et al.
Oncology Reports|February 22, 2008
Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerizationXiaohong Lu, Peter K Vogt, Dale L Boger, et al.
Biomolecules|October 29, 2020
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersChiao-En Wu, Yi-Ru Pan, Chun-Nan Yeh, et al.
Gene|August 19, 2004
Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAsHuiling Liang, Helen Atkins, Rana Abdel-Fattah, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 25, 2016
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP InhibitorsIoannis C Kotsopoulos, Ali Kucukmetin, Asima Mukhopadhyay, et al.
International Journal of Oncology|August 3, 2007
MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-14John J Anderson, Christine Challen, Helen Atkins, et al.
Cancer Cell International|March 23, 2019
<i>TP53</i> mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic responseChiao-En Wu, Tsin Shue Koay, Yi-Hsuan Ho, et al.
Pediatric Blood & Cancer|October 13, 2011
Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcomaKenneth S Rankin, Mike Starkey, John Lunec, et al.
Hybridoma and Hybridomics|May 7, 2002
Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissuesGhassan S Nouman, Brian Angus, John Lunec, et al.
Pageof 8